FOR IMMEDIATE RELEASE

Gene Silencing Technology Unlocks Rapid Weight Loss While Preserving Lean Mass and Preventing Weight Regain

Vancouver, BC, November 23, 2024 – Canary Cure Biotechnologies (canarycure.com) today announced groundbreaking preclinical results for its novel obesity treatment, CCT-217, a first-in-class dual siRNA therapy. CCT-217 utilizes gene silencing technology to achieve rapid weight loss while preserving lean body mass and preventing weight regain when used with incretin therapies.

"CCT-217 represents a paradigm shift in obesity treatment. It drives robust, rapid weight loss primarily by increasing resting energy expenditure, with minimal impact on appetite. This translates to significant fat loss, including visceral fat, while preserving lean body mass at normal levels – crucial for long-term metabolic health. Pre-Clinical studies in Obese mice treated with CCT-217 showed a remarkable 59% improvement over controls normalizing their lean body mass composition to normal lean mice levels. The convenience of twice-yearly dosing and the potential for combination use with incretins to prevent weight regain after dose discontinuation position CCT-217 as a truly groundbreaking therapy for obesity," said Canary Cure CEO, Raj Reddy.

Key Highlights:

• Novel siRNA Gene Silencing: CCT-217 leverages a unique dual siRNA approach to target the ZFP423 gene pathway, increasing resting energy expenditure and promoting weight loss.
• Rapid Weight Loss: Preclinical studies demonstrated robust and rapid weight loss in obese mice superior to current therapies in fewer doses.
• Lean Mass Preservation: Unlike some therapies that can lead to muscle loss, CCT-217 preserves lean body mass to normal lean body composition levels, crucial for metabolic health and overall well-being.
• Reduced Weight Regain: CCT-217 shows promise in preventing weight regain commonly observed after discontinuing incretin therapies like Wegovy and Zepbound. It could be combined with a incretins to prevent weight regain when patients discontinue the incretin.
• Twice-Yearly Dosing: Offers a convenient and long-lasting treatment option with the potential to improve patient compliance.

Professor Lawrence Kazak of McGill University and Canada Research Chair in Adipocyte Biology, a renowned expert in the field of obesity and metabolic health and a member of Canary Cure’s Scientific Advisory Board, commented, “Obesity is a complex disease with considerable health implications. There is a significant unmet need for safe and effective treatments that treats the root causes of the disease. Novel therapies like CCT-217 which focus on harnessing the body’s natural fat-burning capacity offer a promising new approach to not just managing weight, but truly modifying the course of obesity and its associated metabolic complications.”

Mechanism of Action:

CCT-217's dual siRNA approach targets the ZFP423 gene pathway, which plays a crucial role in regulating thermogenesis and energy expenditure. By increasing resting energy expenditure, CCT-217 promotes weight loss without affecting appetite. This mechanism also contributes to the preservation of lean body mass, a key differentiator from other weight loss therapies.

Future Development:

Canary Cure is committed to advancing CCT-217 through clinical development, with plans for Phase 1 trials to evaluate its safety and efficacy, both as a monotherapy and in combination with incretins. The company believes that CCT-217 has the potential to revolutionize obesity treatment by providing a safe, effective, and convenient therapy that addresses the limitations of existing treatments.